Roivant Sciences Ltd. (ROIV) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and welcome to the Roy Vant Fourth Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. Instructions will be given at that time. As a reminder, this call may be recorded. I would like to turn the call over to Stephanie Lee. Please go ahead. Good morning, and thanks for joining today's call to review Roy Vant's financial results for the fourth quarter and fiscal year ended March 31, 2025. I'm Stephanie Lee with Roydent. Presenting today, we have Matt Klein, CEO of Roydent. For those dialing in via conference call, you can find the slides being presented today as well as a press release announcing these updates on our IR website at www.investor.roydent.com. We'll also be providing the current slide numbers as we present to help you follow along. I'd like to remind you that we'll be making certain forward-looking statements during today's presentation. We strongly encourage you to review the information that we have filed with the SEC for more information regarding these forward-looking statements and related risks and uncertainties. And with that, I'll turn it over to Matt. Thank you, Steph, and thank you, everybody, for listening this morning for our fiscal year-end conference call. Good morning. So I'm going to start in the deck here on slide five by saying it's hard to believe this, actually. Not only has it been a very impactful fiscal year, but this is the reporting quarter in which, for example, we generated the data for Botoclumab in my city of Grabs and CIUP. So it's been a very busy year. six months for us to start off at 2025. 2025 is just a really important year for our business, starting with the data we've already generated, which we thin...